AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

GeneDx Corp. (WGS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

101.17

-10.14 (-9.11%)

At close: Feb 20, 2025, 3:59 PM

99.00

-2.14%

After-hours: Feb 20, 2025, 06:09 PM EST

undefined% (undefined)

Bid	96
Market Cap	2.78B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.94
PE Ratio (ttm)	-52.15
Forward PE	n/a
Analyst	Strong Buy

Ask	102
Volume	1,439,718
Avg. Volume (20D)	905,738
Open	108.77
Previous Close	111.31
Day's Range	98.53 - 108.77
52-Week Range	6.79 - 115.60
Beta	undefined

About WGS

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides scien...

[Show more]

Industry Medical - Healthcare Information Services

Sector Healthcare

IPO Date Nov 4, 2020

Employees 1,000

Stock Exchange NASDAQ

Ticker Symbol WGS

Website http://www.genedx.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $80, which is a decrease of -20.93% from the latest price.

Buy 60.00%

Hold 40.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

GeneDx Corp. is scheduled to release its earnings on Apr 28, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 days ago

+47.69%

GeneDx shares are trading higher after the company... Unlock content with Pro Subscription

1 week ago

+9.91%

GeneDx shares are trading higher after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable results in as soon as 48 hours.

News

15 hours ago · accessnewswire.com

GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

1 day ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ:WGS). Such investors are a...

1 day ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

1 day ago · seekingalpha.com

Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy'

GeneDx excels in comprehensive genome and exome testing using a vast genetic database linking 400+ diseases. The company cuts diagnostic times from years to days, enhancing patient outcomes and reduci...

2 days ago · youtube.com

GeneDx CEO on pediatric genetic testing, future of genome sequencing and share surge

Katherine Stueland, GeneDx CEO, joins 'Closing Bell' to discuss company earnings and the future of genome sequencing.

2 days ago · seekingalpha.com

GeneDx Holdings Corp. (WGS) Q4 2024 Earnings Call Transcript

GeneDx Holdings Corp. (NASDAQ:WGS ) Q4 2024 Results Conference Call February 18, 2025 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu...

2 days ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

2 days ago · zacks.com

GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.59 per share a year ago.

2 days ago · businesswire.com

GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

3 days ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / February 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GeneDx Holdings Corp. ("GeneDx" or "the Company") (...

Load More News